INOCARD
InoCard is a biotechnology company and develops AAV-based gene therapy approach for the long-term treatment of congestive heart failure, targeting the calcium-binding protein S100A1.
INOCARD
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2013-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Status:
Active
Similar Organizations
Cardiola
Cardiola is a biotechnology company developing therapeutic systems for the treatment of chronic heart failure.
NeuroTargets
NeuroTargets is a biotechnology company that researches and develops drugs for the treatment of neurological diseases.
More informations about "InoCard"
InoCard - Crunchbase Company Profile & Funding
Organization. InoCard . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. About. InoCard is a biotechnology company and develops AAV-based gene therapy approach for the long-term treatment of congestive heart failure. Acquired by . UniQure . โฆSee details»
InoCard Company Profile 2024: Valuation, Investors, Acquisition
InoCard was founded in 2014. Where is InoCard headquartered? InoCard is headquartered in Heidelberg, Germany. What industry is InoCard in? InoCardโs primary industry is โฆSee details»
uniQure acquires the gene therapy start-up InoCard
Aug 20, 2014 InoCard founders Prof. Patrick Most and Prof. Hugo Katus will join uniQure as Managing Director of uniQure in Germany and Chairman of the Scientific Advisory Board, for Cardiovascular Diseases, respectively. โฆSee details»
AaviGen
Heart Failure is a Pressing Concern. With our teamโs profound grasp of cardiac pathophysiology AaviGen seeks to revolutionise cardiac care by rectifying the aberrant cellular and molecular processes which underpin heart failure.See details»
uniQure Acquires Cardiology Gene Therapy Company InoCard
Aug 11, 2014 Confirmation Code: 5826325. Local - London, United Kingdom: +44(0)20 3427 1917. Local - New York, United States of America: +1212 444 0896. Local - Berlin, Germany: โฆSee details»
InoCard - Overview, News & Similar companies | ZoomInfo.com
InoCard GmbH is a forward-thinking, early-stage biotechnology firm focused on the development of gene therapy approaches for cardiac disease. InoCard has advanced to preclinical proof of โฆSee details»
UniQure acquires InoCard - 2014-08-12 - Crunchbase
Acquired Organization: InoCard InoCard is a biotechnology company and develops AAV-based gene therapy approach for the long-term treatment of congestive heart failure. Acquiring โฆSee details»
uniQure Expands Gene Therapy Stable with InoCard Acquisition
UniQure has acquired InoCard, an early-stage biotechnology company focused on the development of gene therapy products for cardiac disease. genprowebdirectory Facebook โฆSee details»
uniQure Acquires InoCard, Gene Therapy For CHF - Clinical Leader
Aug 14, 2014 InoCard is an early stage biotech company that specializes in developing gene therapy approaches for the treatment of cardiac diseases. The companyโs lead program โฆSee details»
InoCard - MCEI
Inocard GmbH is a Heidelberg-based Medtech venture which has developed a gene therapy for heart insufficiency. The founders Prof. Dr. Hugo Katus, medical director of the Heidelberg โฆSee details»
uniQure Acquires Cardiology Gene Therapy Company InoCard
Aug 12, 2014 uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology โฆSee details»
Uniqure adds heart failure gene therapy with Inocard acquisition
Gene therapy pioneer Uniqure NV is moving into the field of complex disease, by purchasing Inocard GmbH, an early stage German start-up focused on congestive heart failure (CHF), in a โฆSee details»
InoCard | Evaluate
The latest news, comment and analysis about InoCard from the Vantage editorial team.See details»
Marc Lerchenmüller | Life Science Accelerator Baden-Württemberg
He also served on the four-person founding team of InoCard GmbH, a biotechnology start-up that was sold to uniQure N.V. and then entered into a development alliance with Bristol-Myers โฆSee details»
InoCard - Crunchbase
InoCard is a biotechnology company and develops AAV-based gene therapy approach for the long-term treatment of congestive heart failure. Search Crunchbase. Start Free Trial . Chrome โฆSee details»
Organization - INO
INOโs Board of Directors comprises 10 members who are experts in the field and who serve as an interface between the organizationโs activities and the needs of its clients and partners. Each โฆSee details»
INO | Center of Innovation
Helping industries to be more productive and competitive Whether you are an equipment supplier, manufacturer, research centre or government agency, no matter what industry you are in, INO โฆSee details»
Uno (card game) - Wikipedia
Uno cards. Uno (/ ห uห n oส /; from Spanish and Italian for 'one'), stylized as UNO, is a proprietary American shedding-type card game originally developed in 1971 by Merle Robbins in Reading, โฆSee details»
How to Play UNO | Official Rules - Official Game Rules
For two players, there is a slight change of rules: Reverse works like Skip. Play Skip, and you may immediately play another card. If you play a Draw Two or Wild Draw Four card, your opponent โฆSee details»
Uno Card Games | Walmart Canada
Shop all office supplies Paper Writing & colouring Desk organization & filing Scissors Calculators Binders & accessories Staplers, stamps & hole punches Glue & tape Clips, fasteners & rubber โฆSee details»